Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 2
1968 2
1970 6
1972 8
1973 4
1974 15
1975 9
1976 16
1977 16
1978 31
1979 16
1980 25
1981 22
1982 23
1983 24
1984 34
1985 28
1986 29
1987 44
1988 47
1989 36
1990 43
1991 36
1992 45
1993 47
1994 71
1995 54
1996 62
1997 65
1998 64
1999 49
2000 58
2001 56
2002 70
2003 66
2004 75
2005 71
2006 65
2007 74
2008 94
2009 123
2010 106
2011 145
2012 156
2013 183
2014 253
2015 238
2016 253
2017 250
2018 237
2019 218
2020 226
2021 214
2022 143
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,836 results
Results by year
Filters applied: . Clear all
Page 1
Glucose metabolism during rotational shift-work in healthcare workers.
Sharma A, Laurenti MC, Dalla Man C, Varghese RT, Cobelli C, Rizza RA, Matveyenko A, Vella A. Sharma A, et al. Diabetologia. 2017 Aug;60(8):1483-1490. doi: 10.1007/s00125-017-4317-0. Epub 2017 May 27. Diabetologia. 2017. PMID: 28551698 Free PMC article. Clinical Trial.
RESULTS: Postprandial glycaemic excursion was higher during the night shift (38133 vs 58048 mmol/l per 5 h, p<0.01). The time to peak insulin and C-peptide and nadir glucagon suppression in response to meal ingestion was also delayed during the night shift. ...
RESULTS: Postprandial glycaemic excursion was higher during the night shift (38133 vs 58048 mmol/l per 5 h, p<0.01). The time to peak ins …
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T, Mari A, DeVries JH, Urva S, Li J, Pratt EJ, Coskun T, Thomas MK, Mather KJ, Haupt A, Milicevic Z. Heise T, et al. Lancet Diabetes Endocrinol. 2022 Jun;10(6):418-429. doi: 10.1016/S2213-8587(22)00085-7. Epub 2022 Apr 22. Lancet Diabetes Endocrinol. 2022. PMID: 35468322 Clinical Trial.
Secondary endpoints included the effect of tirzepatide versus semaglutide on the change in clamp disposition index from baseline to week 28 of treatment, glucose control, total insulin secretion rate, M value (insulin sensitivity), and fasting and postprandial glucagon con …
Secondary endpoints included the effect of tirzepatide versus semaglutide on the change in clamp disposition index from baseline to week 28 …
Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.
Battelino T, Tehranchi R, Bailey T, Dovc K, Melgaard A, Yager Stone J, Woerner S, von dem Berge T, DiMeglio L, Danne T. Battelino T, et al. Pediatr Diabetes. 2021 Aug;22(5):734-741. doi: 10.1111/pedi.13220. Epub 2021 Jun 9. Pediatr Diabetes. 2021. PMID: 33934456 Free PMC article. Clinical Trial.
BACKGROUND: Dasiglucagon, a next-generation, ready-to-use aqueous glucagon analog formulation, has been developed to treat severe hypoglycemia in individuals with diabetes. ...The most frequent adverse events were nausea and vomiting, as expected with glucagon treat …
BACKGROUND: Dasiglucagon, a next-generation, ready-to-use aqueous glucagon analog formulation, has been developed to treat severe hyp …
Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial.
Pieber TR, Aronson R, Hövelmann U, Willard J, Plum-Mörschel L, Knudsen KM, Bandak B, Tehranchi R. Pieber TR, et al. Diabetes Care. 2021 Jun 1;44(6):1361-1367. doi: 10.2337/dc20-2995. Diabetes Care. 2021. PMID: 35239971 Free PMC article. Clinical Trial.

The primary comparison was dasiglucagon versus placebo; reconstituted lyophilized glucagon was included as reference. RESULTS: Median (95% CI) time to recovery was 10 (10, 10) minutes for dasiglucagon compared with 40 (30, 40) minutes for placebo (P < 0.001); the corres

…
The primary comparison was dasiglucagon versus placebo; reconstituted lyophilized glucagon was included as reference. RESULTS: Median …
Effects of common cold and concomitant administration of nasal decongestant on the pharmacokinetics and pharmacodynamics of nasal glucagon in otherwise healthy participants: A randomized clinical trial.
Guzman CB, Dulude H, Piché C, Rufiange M, Sadoune AA, Rampakakis E, Carballo D, Triest M, Zhang MX, Zhang S, Tafreshi M, Sicard E. Guzman CB, et al. Diabetes Obes Metab. 2018 Mar;20(3):646-653. doi: 10.1111/dom.13134. Epub 2017 Nov 19. Diabetes Obes Metab. 2018. PMID: 29053231 Free PMC article. Clinical Trial.
AIMS: Nasal glucagon (NG) is a nasally-administered glucagon powder, absorbed through the nasal mucosa, designed for treatment of severe hypoglycaemia. ...Common adverse events (transient lacrimation, nasal discomfort, rhinorrhea and nausea) were more frequent in bo …
AIMS: Nasal glucagon (NG) is a nasally-administered glucagon powder, absorbed through the nasal mucosa, designed for treatment …
A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients.
Baker AL, Jaspan JB, Haines NW, Hatfield GE, Krager PS, Schneider JF. Baker AL, et al. Gastroenterology. 1981 Jun;80(6):1410-4. Gastroenterology. 1981. PMID: 7014349 Clinical Trial.
A randomized, double-blind, controlled trial of insulin and glucagon infusion was conducted in 50 patients with acute alcoholic hepatitis. ...Six control and 2 treatment patients died from liver failure during study, and another treatment patient died from hypoglycemia. In …
A randomized, double-blind, controlled trial of insulin and glucagon infusion was conducted in 50 patients with acute alcoholic hepat …
Prolonged Glucagon Infusion Does Not Affect Energy Expenditure in Individuals with Overweight/Obesity: A Randomized Trial.
Whytock KL, Carnero EA, Vega RB, Tillner J, Bock C, Chivukula K, Yi F, Meyer C, Smith SR, Sparks LM. Whytock KL, et al. Obesity (Silver Spring). 2021 Jun;29(6):1003-1013. doi: 10.1002/oby.23141. Obesity (Silver Spring). 2021. PMID: 34029448 Clinical Trial.
OBJECTIVE: The aim of this study was to determine the effects of prolonged (72 hours) glucagon administration at a low dose (LD) (12.5 ng/kg/min) and high dose (HD) (25 ng/kg/min) on energy expenditure (EE) in healthy individuals with overweight or obesity. ...Blood was sa …
OBJECTIVE: The aim of this study was to determine the effects of prolonged (72 hours) glucagon administration at a low dose (LD) (12. …
Glucagon and barium enema examinations: a controlled clinical trial.
Harned RK, Stelling CB, Williams S, Wolf GL. Harned RK, et al. AJR Am J Roentgenol. 1976 May;126(5):981-4. doi: 10.2214/ajr.126.5.981. AJR Am J Roentgenol. 1976. PMID: 178243 Clinical Trial.
In addition, 50 patients were given either placebo or 2 mg glucagon prior to barium enema examination in a double-blind study. ...Adverse reactions did not occur frequently enough to allow confident comparison of placebo and glucagon. It is concluded that the use of …
In addition, 50 patients were given either placebo or 2 mg glucagon prior to barium enema examination in a double-blind study. ...Adv …
High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial.
Petersen KM, Bøgevig S, Riis T, Andersson NW, Dalhoff KP, Holst JJ, Knop FK, Faber J, Petersen TS, Christensen MB. Petersen KM, et al. J Am Heart Assoc. 2020 Nov 3;9(21):e016828. doi: 10.1161/JAHA.120.016828. Epub 2020 Oct 26. J Am Heart Assoc. 2020. PMID: 33103603 Free PMC article. Clinical Trial.
We therefore investigated hemodynamic effects and safety of high-dose glucagon with and without concomitant beta-blockade. Methods and Results In a randomized crossover study, 10 healthy men received combinations of esmolol (1.25 mg/kg bolus+0.75 mg/kg/min infusion), gl …
We therefore investigated hemodynamic effects and safety of high-dose glucagon with and without concomitant beta-blockade. Methods an …
Insulin secretion and action and the response of endogenous glucose production to a lack of glucagon suppression in nondiabetic subjects.
Adams JD, Egan AM, Laurenti MC, Schembri Wismayer D, Bailey KR, Cobelli C, Dalla Man C, Vella A. Adams JD, et al. Am J Physiol Endocrinol Metab. 2021 Nov 1;321(5):E728-E736. doi: 10.1152/ajpendo.00284.2021. Epub 2021 Oct 18. Am J Physiol Endocrinol Metab. 2021. PMID: 34658253 Free PMC article. Clinical Trial.
Type 2 diabetes is a disease characterized by impaired insulin secretion and defective glucagon suppression in the postprandial period. We examined the effect of impaired glucagon suppression on glucose concentrations and endogenous glucose production (EGP) at diffe …
Type 2 diabetes is a disease characterized by impaired insulin secretion and defective glucagon suppression in the postprandial perio …
3,836 results